Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics Inc (NQ: HOWL )

5.830 -0.150 (-2.51%)
Streaming Delayed Price Updated: 12:39 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Werewolf Therapeutics Inc

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in May Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.